Denosumab: AHFS 92:24

Andrew Wilcock; Sarah Charlesworth; Claire Stark Toller; Rahul Girish; Mary Mihalyo; Paul Howard

doi:10.1016/j.jpainsymman.2018.05.021

Denosumab: AHFS 92:24

J Pain Symptom Manage. 2018 Aug;56(2):295-301. doi: 10.1016/j.jpainsymman.2018.05.021. Epub 2018 Jun 2.

Authors

Andrew Wilcock¹, Sarah Charlesworth², Claire Stark Toller², Rahul Girish², Mary Mihalyo², Paul Howard²

Affiliations

¹ University of Nottingham (A.W.), Nottingham, United Kingdom; University Hospitals (S.C.), Nottingham, United Kingdom; Countess Mountbatten House (C.S.T), University Hospital Southampton; University of Nottingham (R.G.), Nottingham, United Kingdom; Mylan School of Pharmacy (M.M.), Duquesne University, Pittsburgh, Pennsylvania, USA and Mountbatten Hospice (P.H.), Isle of Wight, United Kingdom. Electronic address: andrew.wilcock@nottingham.ac.uk.
² University of Nottingham (A.W.), Nottingham, United Kingdom; University Hospitals (S.C.), Nottingham, United Kingdom; Countess Mountbatten House (C.S.T), University Hospital Southampton; University of Nottingham (R.G.), Nottingham, United Kingdom; Mylan School of Pharmacy (M.M.), Duquesne University, Pittsburgh, Pennsylvania, USA and Mountbatten Hospice (P.H.), Isle of Wight, United Kingdom.

PMID: 29864491
DOI: 10.1016/j.jpainsymman.2018.05.021

Abstract

Therapeutic Reviews aim to provide essential independent information for health professionals about drugs used in palliative and hospice care. Additional content is available on www.palliativedrugs.com. Country-specific books (Hospice and Palliative Care Formulary USA, and Palliative Care Formulary, British and Canadian editions) are also available and can be ordered from www.palliativedrugs.com. The series editors welcome feedback on the articles (hq@palliativedrugs.com).

Publication types

Review

MeSH terms

Bone Density Conservation Agents / adverse effects
Bone Density Conservation Agents / therapeutic use*
Denosumab / adverse effects
Denosumab / therapeutic use*
Humans

Substances

Bone Density Conservation Agents
Denosumab